Voluntary Faculty
Voluntary faculty are typically clinicians or others who are employed outside of the School but make significant contributions to department programs at the medical center or at affiliate institutions.
Voluntary rank detailsClara Fonteneau, PhD
Clinical InstructorAbout
Research
Publications
2025
A common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns
Berkovitch L, Lee K, Ji J, Helmer M, Rahmati M, Demsar J, Kraljic A, Matkovic A, Tamayo Z, Murray J, Repovs G, Krystal J, Martin W, Fonteneau C, Anticevic A. A common symptom geometry of mood improvement under sertraline and placebo associated with distinct neural patterns. Psychological Medicine 2025, 55: e185. PMID: 40611472, PMCID: PMC12270277, DOI: 10.1017/s0033291725100962.Peer-Reviewed Original ResearchConceptsMechanisms of Major depressive disordersGlobal brain connectivitySymptom improvementClinical Global Impression ScaleGlobal Impression ScaleMajor depressive disorderManic-like symptomsMeasures of clinical improvementAntidepressant treatmentImpression ScaleDepressive disorderNeural profilesMood improvementSuicidal ideasPattern of clinical improvementSymptom ScaleClinical scalesNeural patternsSertralineBrain connectivityNeural circuitsIndividual itemsPatients' scoresClinical improvementImproved scoresModulation of dopaminergic transmission and brain activity by frontotemporal tDCS: A multimodal PET-MR imaging study
Fonteneau C, Merida I, Redoute J, Haesebaert F, Lancelot S, Costes N, Mondino M, Brunelin J. Modulation of dopaminergic transmission and brain activity by frontotemporal tDCS: A multimodal PET-MR imaging study. Brain Stimulation 2025, 18: 1065-1073. PMID: 40340023, DOI: 10.1016/j.brs.2025.05.006.Peer-Reviewed Original ResearchTranscranial direct current stimulationPositron emission tomographyArterial spin labelingMagnetic resonance imagingWhite matter microstructural integrityModulation of dopaminergic transmissionParallel-group studyNo significant effects of tDCSOptimization of therapeutic strategiesNon-displaceable binding potentialEffects of transcranial direct current stimulationCerebral blood flowNeurophysiological mechanismsDiffusion weighted imagingMicrostructural integrityPET-MR imagingActive transcranial direct current stimulationDopaminergic transmissionDouble-blindSimultaneous positron emission tomographyDopamine releaseDopamine transmissionClinical benefitDirect current stimulationDopamine system481. Resting-State Perfusion and Executive Control Task Performance in Psychosis Spectrum Disorder
Cail C, Rahmati M, Fonteneau C, Zharyy C, Forselius-Bielen K, Beri E, Miller E, Santamauro N, Anticevic A, Cortes-Briones J, Proulx E, Preller K, Cho Y. 481. Resting-State Perfusion and Executive Control Task Performance in Psychosis Spectrum Disorder. Biological Psychiatry 2025, 97: s295-s296. DOI: 10.1016/j.biopsych.2025.02.719.Peer-Reviewed Original Research533. Bold Signal Can Capture Individual Variability in Spatial Working Memory Deficits Induced by Ketamine
Rahmati M, Moujaes F, Purg N, Fonteneau C, Santamauro N, Tamayo Z, Repovs G, Preller K, Anticevic A, Fineberg S, Murray J, Krystal J, Cho Y. 533. Bold Signal Can Capture Individual Variability in Spatial Working Memory Deficits Induced by Ketamine. Biological Psychiatry 2025, 97: s317. DOI: 10.1016/j.biopsych.2025.02.772.Peer-Reviewed Original Research541. Identifying Neurobiological Mechanisms of Psychosis-Risk
Brege S, Lee K, Tamayo Z, Grent-'t-Jong T, Anticevic A, Uhlhaas P, Cho Y, Fonteneau C. 541. Identifying Neurobiological Mechanisms of Psychosis-Risk. Biological Psychiatry 2025, 97: s321. DOI: 10.1016/j.biopsych.2025.02.780.Peer-Reviewed Original Research478. Cross-Site Quality Assessment of Data From a Pharmacologic Neuroimaging Trial Targeting Working Memory Neural Circuits in Schizophrenia
Zharyy C, Fonteneau C, Rahmati M, Price A, Gil R, Govil P, Grinband J, Gur R, Haubold N, Heffernan Z, Lu J, Mayer M, Ranganathan M, Santamauro N, Tamayo Z, Van Snellenberg J, Wolf D, Group T, Anticevic A, Lieberman J, Kantrowitz J, Abi-Dargham A, Gur R, Krystal J, Cho Y. 478. Cross-Site Quality Assessment of Data From a Pharmacologic Neuroimaging Trial Targeting Working Memory Neural Circuits in Schizophrenia. Biological Psychiatry 2025, 97: s294. DOI: 10.1016/j.biopsych.2025.02.716.Peer-Reviewed Original Research
2024
Human brain state dynamics are highly reproducible and associated with neural and behavioral features
Lee K, Ji J, Fonteneau C, Berkovitch L, Rahmati M, Pan L, Repovš G, Krystal J, Murray J, Anticevic A. Human brain state dynamics are highly reproducible and associated with neural and behavioral features. PLOS Biology 2024, 22: e3002808. PMID: 39316635, PMCID: PMC11421804, DOI: 10.1371/journal.pbio.3002808.Peer-Reviewed Original ResearchConceptsCo-activation patternsResting-state functional magnetic resonance imagingFunctional magnetic resonance imagingBehavioral featuresNeural variationsMoment-to-moment changesSingle-subject levelBrain state dynamicsEmotion regulationHealthy young adultsBehavioral phenotypesCognitive functionSubstance useNeural activityNeuroimaging markersNeural featuresYoung adultsMagnetic resonance imagingCo-activationResonance imagingCo-variationNeuroimagingIndividualsEmotionsFunctional outcomesKetamine induces multiple individually distinct whole-brain functional connectivity signatures
Moujaes F, Ji J, Rahmati M, Burt J, Schleifer C, Adkinson B, Savic A, Santamauro N, Tamayo Z, Diehl C, Kolobaric A, Flynn M, Rieser N, Fonteneau C, Camarro T, Xu J, Cho Y, Repovs G, Fineberg S, Morgan P, Seifritz E, Vollenweider F, Krystal J, Murray J, Preller K, Anticevic A. Ketamine induces multiple individually distinct whole-brain functional connectivity signatures. ELife 2024, 13: e84173. PMID: 38629811, PMCID: PMC11023699, DOI: 10.7554/elife.84173.Peer-Reviewed Original ResearchConceptsResponse to ketamineAcute ketamineBehavioral effectsQuantified resting-state functional connectivityEffects of acute ketamineSymptom variationResting-state functional connectivityTreatment-resistant depressionFunctional connectivity signaturesGlobal brain connectivitySingle-subject levelInter-individual variabilityPlacebo-controlled studyFunctional connectivityConnectivity signaturesBrain connectivityHealthy participantsSingle-blind placebo-controlled studyNeural variationsTreatment conditionsKetamineGene expression targetsPharmacological biomarkersPilot awardParvalbuminAccelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis
Wannan C, Nelson B, Addington J, Allott K, Anticevic A, Arango C, Baker J, Bearden C, Billah T, Bouix S, Broome M, Buccilli K, Cadenhead K, Calkins M, Cannon T, Cecci G, Chen E, Cho K, Choi J, Clark S, Coleman M, Conus P, Corcoran C, Cornblatt B, Diaz-Caneja C, Dwyer D, Ebdrup B, Ellman L, Fusar-Poli P, Galindo L, Gaspar P, Gerber C, Glenthøj L, Glynn R, Harms M, Horton L, Kahn R, Kambeitz J, Kambeitz-Ilankovic L, Kane J, Kapur T, Keshavan M, Kim S, Koutsouleris N, Kubicki M, Kwon J, Langbein K, Lewandowski K, Light G, Mamah D, Marcy P, Mathalon D, McGorry P, Mittal V, Nordentoft M, Nunez A, Pasternak O, Pearlson G, Perez J, Perkins D, Powers A, Roalf D, Sabb F, Schiffman J, Shah J, Smesny S, Spark J, Stone W, Strauss G, Tamayo Z, Torous J, Upthegrove R, Vangel M, Verma S, Wang J, Rossum I, Wolf D, Wolff P, Wood S, Yung A, Agurto C, Alvarez-Jimenez M, Amminger P, Armando M, Asgari-Targhi A, Cahill J, Carrión R, Castro E, Cetin-Karayumak S, Chakravarty M, Cho Y, Cotter D, D’Alfonso S, Ennis M, Fadnavis S, Fonteneau C, Gao C, Gupta T, Gur R, Gur R, Hamilton H, Hoftman G, Jacobs G, Jarcho J, Ji J, Kohler C, Lalousis P, Lavoie S, Lepage M, Liebenthal E, Mervis J, Murty V, Nicholas S, Ning L, Penzel N, Poldrack R, Polosecki P, Pratt D, Rabin R, Eichi H, Rathi Y, Reichenberg A, Reinen J, Rogers J, Ruiz-Yu B, Scott I, Seitz-Holland J, Srihari V, Srivastava A, Thompson A, Turetsky B, Walsh B, Whitford T, Wigman J, Yao B, Yuen H, Ahmed U, Byun A, Chung Y, Do K, Hendricks L, Huynh K, Jeffries C, Lane E, Langholm C, Lin E, Mantua V, Santorelli G, Ruparel K, Zoupou E, Adasme T, Addamo L, Adery L, Ali M, Auther A, Aversa S, Baek S, Bates K, Bathery A, Bayer J, Beedham R, Bilgrami Z, Birch S, Bonoldi I, Borders O, Borgatti R, Brown L, Bruna A, Carrington H, Castillo-Passi R, Chen J, Cheng N, Ching A, Clifford C, Colton B, Contreras P, Corral S, Damiani S, Done M, Estradé A, Etuka B, Formica M, Furlan R, Geljic M, Germano C, Getachew R, Goncalves M, Haidar A, Hartmann J, Jo A, John O, Kerins S, Kerr M, Kesselring I, Kim H, Kim N, Kinney K, Krcmar M, Kotler E, Lafanechere M, Lee C, Llerena J, Markiewicz C, Matnejl P, Maturana A, Mavambu A, Mayol-Troncoso R, McDonnell A, McGowan A, McLaughlin D, McIlhenny R, McQueen B, Mebrahtu Y, Mensi M, Hui C, Suen Y, Wong S, Morrell N, Omar M, Partridge A, Phassouliotis C, Pichiecchio A, Politi P, Porter C, Provenzani U, Prunier N, Raj J, Ray S, Rayner V, Reyes M, Reynolds K, Rush S, Salinas C, Shetty J, Snowball C, Tod S, Turra-Fariña G, Valle D, Veale S, Whitson S, Wickham A, Youn S, Zamorano F, Zavaglia E, Zinberg J, Woods S, Shenton M. Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ): Rationale and Study Design of the Largest Global Prospective Cohort Study of Clinical High Risk for Psychosis. Schizophrenia Bulletin 2024, 50: 496-512. PMID: 38451304, PMCID: PMC11059785, DOI: 10.1093/schbul/sbae011.Peer-Reviewed Original ResearchClinical high-risk individualsClinical high riskNational Institute of Mental HealthInstitute of Mental HealthAttenuated positive symptomsPersistent negative symptomsTransition to psychosisCHR statusHigh riskNegative symptomsPositive symptomsAnxiety symptomsPsychosocial functioningCognitive dataOutcomes of individualsDigital health technologiesDaily surveysPsychosisSCZPublic health needsMental healthNovel pharmacological interventionsSchizophreniaClinical outcomesHealth needs